research use only

Batimastat (BB-94) MMP inhibitor

Name: Batimastat (BB-94)
Brand: Selleck Chemicals
SKU: S7155
Rating: 5 (41 reviews)

Cat.No.S7155

Batimastat (BB-94) is a potent, broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-1, MMP-2, MMP-9, MMP-7 and MMP-3 with IC50 of 3 nM, 4 nM, 4 nM, 6 nM and 20 nM, respectively. It also inhibits the activitity of other metalloproteases, such as ADAM17.

Chemical Structure

Molecular Weight: 477.64

Jump to

Quality Control

Batch: Purity: 99.02%

99.02

Related Targets	HDAC Caspase Proteasome Secretase HCV Protease Cysteine Protease DPP Tyrosinase HIV Protease Serine Protease
Other MMP Inhibitors	Ilomastat (GM6001) Marimastat (BB-2516) SB-3CT T-5224 Nobiletin MMP-9-IN-1 NSC 405020 1, 10-Phenanthroline monohydrate JNJ0966 Cordycepin

Cell Culture, Treatment & Working Concentration

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
Sf9 insect cells	Function assay			Inhibition of human matrix metalloprotease-2 expressed in Sf9 insect cells, IC50=0.013 μM	15582436
Sf9 insect cells	Function assay			Inhibition of human matrix metalloprotease-9 expressed in Sf9 insect cells, IC50=0.025 μM	15582436
HT1080	Function assay			In vitro inhibitory activity against matrix metalloprotease 2 isolated from human HT1080 fibrosarcoma cells induced with TNF, IC50=0.0021μM	9873712
white blood cells	Antifibrotic assay	25 to 150 mg/kg	13 days	Antifibrotic activity in bleomycin-induced C57B1/6 mouse model assessed as inhibition of white blood cells in bronchoalveolar lavage at 25 to 150 mg/kg, po bid administered 2 hrs prior bleomycin induction for 13 days	15582436
RPM18866	Function assay			Tested for inhibition against CD23 (IgE receptor) proteolysis in membranes derived from RPM18866 cells ( a human B-cell line), IC50=0.1μM	9871622
RPM18866	Function assay			Inhibition against CD23 (IgE receptor) proteolysis in membranes derived from RPM18866 cells, IC50=0.1μM	9871623
Click to View More Cell Line Experimental Data

Chemical Information, Storage & Stability

Molecular Weight	477.64	Formula	C₂₃H₃₁N₃O₄S₂	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	130370-60-4	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			Smiles	CC(C)CC(C(CSC1=CC=CS1)C(=O)NO)C(=O)NC(CC2=CC=CC=C2)C(=O)NC

Solubility

In vitro
Batch:

DMSO : 96 mg/mL (200.98 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	6.000mg/ml (12.56mM)	Taking the 1 mL working solution as an example, add 50 μL of 120 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to make it clear; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.250mg/ml (2.62mM)	Taking the 1 mL working solution as an example, add 50 μL of 25 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	MMP-1 3 nM MMP-2 4 nM MMP-9 4 nM MMP-7 6 nM MMP-3 20 nM
In vitro	Batimastat (BB-94) is a potent, broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-1, MMP-2, MMP-9, MMP-7 and MMP-3 with IC50 of 3 nM, 4 nM, 4 nM, 6 nM and 20 nM, respectively. This compound exhibits an unexpected binding geometry, with the thiophene ring deeply inserted into the primary specificity site.
Kinase Assay	Enzyme assays
Kinase Assay	In enzyme assays, IC50s are determined for Batimastat (BB-94) in vitro against different metalloproteinases.
In vivo	Batimastat (BB-94) can inhibit metastatic spread and growth of B16-BL6 murine melanoma. In an orthotopic colon tumor model in mice, treatment with this compound results in inhibition of primary tumor growth (by 50%), local/regional spread (from 67% to 35%), and distant metastasis (from 30% to 10%). It reduces in vivo growth of experimental hemangiomas, most probably by blocking endothelial cell recruitment by the transformed cells or by interfering with cell organization in vascular structures.
References	[1] https://pubmed.ncbi.nlm.nih.gov/8050828/ [2] https://pubmed.ncbi.nlm.nih.gov/8610113/ [3] https://pubmed.ncbi.nlm.nih.gov/8062271/ [4] https://pubmed.ncbi.nlm.nih.gov/7535861/

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):